These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 33811006

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Falini B, De Carolis L, Tiacci E.
    Blood; 2022 Apr 14; 139(15):2294-2305. PubMed ID: 35143639
    [Abstract] [Full Text] [Related]

  • 4. Hairy cell leukemia: update and current therapeutic approach.
    Salam L, Abdel-Wahab O.
    Curr Opin Hematol; 2015 Jul 14; 22(4):355-61. PubMed ID: 26049757
    [Abstract] [Full Text] [Related]

  • 5. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
    Wei C, Jin XX, Cai H, Wang X, Zhuang JL, Zhou DB.
    Zhonghua Nei Ke Za Zhi; 2023 Apr 01; 62(4):416-421. PubMed ID: 37032137
    [Abstract] [Full Text] [Related]

  • 6. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
    Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T.
    Blood; 2016 Jun 09; 127(23):2847-55. PubMed ID: 26941398
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A, Žák P, Jurková T, Arpáš T, Brychtová Y, Vašíková A, Hrabčáková V, Prchlíková A, Filipová M, Doubek M.
    Hematol Oncol; 2024 May 09; 42(3):e3280. PubMed ID: 38741354
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. BRAF in the cross-hairs.
    Geyer MB, Abdel-Wahab O, Tallman MS.
    Expert Rev Hematol; 2019 Mar 09; 12(3):183-193. PubMed ID: 30782032
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
    Falini B, Tiacci E.
    Hematol Oncol; 2019 Jun 09; 37 Suppl 1():30-37. PubMed ID: 31187521
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hairy cell leukemia: Past, present and future.
    Getta BM, Park JH, Tallman MS.
    Best Pract Res Clin Haematol; 2015 Dec 09; 28(4):269-72. PubMed ID: 26614906
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
    Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, Grever MR, Rai KR, Shukla M, Vemuri S, Montoya S, Taylor J, Abdel-Wahab O, Tallman MS, Park JH.
    Blood; 2022 Dec 22; 140(25):2663-2671. PubMed ID: 35930750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.
    Ferenczi K, Nagy ZF, Istenes I, Eid H, Bödör C, Timár B, Demeter J.
    Pathol Oncol Res; 2023 Dec 22; 29():1611378. PubMed ID: 38025907
    [Abstract] [Full Text] [Related]

  • 19. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
    Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E.
    Blood; 2015 Feb 19; 125(8):1207-16. PubMed ID: 25480661
    [Abstract] [Full Text] [Related]

  • 20. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
    Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G.
    Haematologica; 2013 Feb 19; 98(2):e20-2. PubMed ID: 23300174
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.